ELN 2022 AML Genetic Risk Classification
ELN 2022 AML genetic-risk stratification: core-binding-factor / bZIP CEBPA / NPM1 without FLT3-ITD favor a favorable category, while adverse cytogenetic-molecular lesions drive an adverse category, with the remainder intermediate.
Open the calculator → Runs in your browser. Data leaves only if you deliberately send a problem report from the interactive tool.
Example
- Mutated NPM1
- Yes
Result: ELN 2022 AML risk: Favorable — driven by mutated NPM1 without FLT3-ITD.
The tool opens with these values already filled in. Replace them with your own.
What the result means
- Categories
- Favorable: CBF-AML, bZIP CEBPA, or NPM1-mut without FLT3-ITD. Adverse: complex/monosomal karyotype, −5/−7/−17p, TP53, high-risk molecular or fusion lesions. Intermediate: everything else.
- Precedence
- An adverse lesion overrides an otherwise-favorable NPM1; any FLT3-ITD moves NPM1-mutated AML from favorable to intermediate. A classification, not a therapy order.
What you enter
- Core-binding-factor AML — t(8;21) or inv(16)/t(16;16) (favorable)
- bZIP in-frame CEBPA mutation (favorable)
- Mutated NPM1 (favorable if no FLT3-ITD)
- FLT3-ITD present
- Any adverse cytogenetic / molecular lesion
How this is calculated
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. Read the source ↗
A reference and educational tool. Not medical, legal, or financial advice, and not a substitute for clinician judgment.